Opko Invests in New Technologies, Raising Questions About the Company's Focus on RNAi

Although RNAi had long been a key aspect of Opko's technology portfolio, the failure of its AMD drug in phase III and a series of recent investments in other technologies raises questions about its interest in siRNA drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories